NASDAQ:NBP

Novabridge Biosciences Q3 2025 Earnings Results & Report

Novabridge Biosciences logo
$0.82 +0.03 (+3.89%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+1.67%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novabridge Biosciences reported Q3 2025 earnings on December 18, 2025. The company reported EPS of -$0.0690.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Novabridge Biosciences EPS Results

Actual EPS
-$0.0690
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novabridge Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Novabridge Biosciences Q3 2025 Earnings FAQ

Novabridge Biosciences (NASDAQ:NBP) reported earnings of -$0.0690 per share for Q3 2025. The report was announced on Thursday, December 18, 2025.

Novabridge Biosciences Earnings Headlines

The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
Brokers Offer Predictions for NBP FY2026 Earnings
See More Novabridge Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novabridge Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novabridge Biosciences and other key companies, straight to your email.

About Novabridge Biosciences

Novabridge Biosciences (NASDAQ:NBP) (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival.

The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets. These products remain in clinical development and are not necessarily approved for commercial use.

Novabridge Biosciences was founded in 2016 and historically maintained operations and development activities in both China and the United States. The company has since emphasized a more globally oriented, U.S.-focused development strategy while continuing to advance selected oncology programs through clinical studies and potential strategic partnerships. Dr. Joan Shen, a biopharmaceutical executive and physician, is the company’s founder and has served in senior leadership roles.

View Novabridge Biosciences Profile